Fierce Biotech June 5, 2023
By Sarah Moore Reviewed by Danielle Ellis, B.Sc.

The COVID-19 pandemic highlighted the global burden of mental health disorders. In the US, rates of anxiety, depression, and substance use disorder have all risen following the pandemic. The need to prioritize mental health is more obvious than ever, and large and small companies have responded by accelerating innovation in this area.

The growing field of biotechnology is one of the most important driving forces in developing novel treatments for mental health disorders. While breakthroughs in the biotechnology industry over the past two decades have rarely focussed on mental illness, times are changing. The biotechnology market, which was valued at $1.37 trillion in 2022 and is expected to grow at a CAGR of 13.96% from 2023 until 2030, is poised...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mental Health, Pharma / Biotech, Provider
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
Regeneron expands in gene editing with Mammoth deal

Share This Article